Dr. Edward P. Feener received his Ph.D. in Biochemistry from Boston University and completed postdoctoral training at the Joslin Diabetes Center and Harvard Medical School. He is a co-founder of KalVista and joined as Chief Scientific Officer in 2016. Previously, he was an Associate Professor of Medicine at Harvard Medical School and Senior Investigator in the Section on Vascular Cell Biology at Joslin Diabetes Center. He has 30 years of research experience in vascular biology and diabetic complications. His laboratory has performed pioneering research on the kallikrein kinin system and was the first to identify plasma kallikrein as a potential therapeutic target for diabetic macular edema. He has published over 100 scientific articles and has served on multiple national and international scientific research review committees.
Rebecca L. Davie, based in
Salisbury, Wiltshire, United Kingdom, is currently a Team Leader at Kalvista
Pharmaceuticals Limited, bringing experience from previous roles at Vantia LTD,
Kalvista Pharmaceuticals Limited and Evotec. Dr. Davie holds a 2000–2003 Doctor
of Philosophy (PhD) in Organic Chemistry at University of Nottingham. Dr. Davie
specializes in biotechnology, drug discovery, chemistry, drug development,
research and development (R&D), and more.
Dr. Nivetha Murugesan is currently working at
KalVista Pharmaceuticals, Inc., starting as a Senior Scientist in 2016, then
progressing to Principal Scientist in 2019, and currently serving as an
Associate Director since 2022. Prior to the role at KalVista Pharmaceuticals,
she worked as a Postdoctoral Research Fellow at Joslin Diabetes Center from 2013
to 2016. Before that, she was a Postdoctoral Fellow at the University of
Connecticut Health Center from 2011 to 2012, focusing on immuno-LCM/qRT-PCR-aided profiling of tissue-compartment-specific inflammatory gene responses
during neuroinflammation. Dr. Nivetha’s education history begins with their undergraduate studies at
Anna University, where they pursued a Bachelor’s degree in Biotechnology from 1997 to 2001.
Following this, they attended the Singapore-MIT Alliance (SMA) from 2001 to
2002, obtaining a Master of Science degree in Biotechnology. Dr. Nivetha
started her career as a Graduate Research Assistant (PhD student) at the
University of Connecticut Health Center in 2005 and completed her Ph.D. in
2011.
Dr. Chris M. Yea holds a BSc and PhD in Biochemistry from the University of Bristol, UK. Following post-doctoral work, he spent several years at Roussel-UCLAF and Hoechst Marion Roussel before joining Ferring Pharmaceuticals. Chris led the Biology group and was responsible for the transition of candidates into development. In 2008, Chris co-led the spin-out of Vantia Ltd. and most recently was Chief Operating Officer where he was responsible for development activities through Phase 3 trials. In his position as Chief Development Officer, Chris is responsible for all development-related activities within KalVista Pharmaceuticals.
